| Joseph Peter Holicki, DO | |
|
142 E Chicago Rd, Coldwater, MI 49036-8423 | |
| (517) 279-7927 | |
| (517) 278-3393 |
| Full Name | Joseph Peter Holicki |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 34 Years |
| Location | 142 E Chicago Rd, Coldwater, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689660920 | NPI | - | NPPES |
| 3519504 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 5101010943 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Promedica Coldwater Regional Hospital | Coldwater, MI | Hospital |
| Cameron Memorial Community Hospital Inc | Angola, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Holicki Eye Centers, P.c. | 3476533324 | 4 |
| Holicki Eye Centers, P.c. | 3476533324 | 4 |
News Archive
Based on the preliminary findings from the ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial, Eisai Inc. announced today that the company will not submit marketing authorization applications to regulatory authorities in the United States, the European Union and Japan by the end of the fiscal year (March 31, 2011), as previously planned.
Nearly one-third of people living with tuberculosis in the U.S. are unaware of their HIV status, according to a study published Friday in CDC's Morbidity and Mortality Weekly Report, Reuters reports (Dunham, Reuters, 10/25).
Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three months ended March 31, 2010.
StockPreacher.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
As the UN Special Rapporteur on maternal mortality in India points out there is a 'yawning gulf between commendable maternal mortality policies and their urgent, focused, sustained, systematic and effective implementation', the May issue of Reproductive Health Matters explores the causes and impact of this gap, but also highlights hopeful signs of progress.
› Verified 4 days ago
| Entity Name | Holicki Optical Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386637957 PECOS PAC ID: 9234128604 Enrollment ID: O20040511000117 |
News Archive
Based on the preliminary findings from the ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial, Eisai Inc. announced today that the company will not submit marketing authorization applications to regulatory authorities in the United States, the European Union and Japan by the end of the fiscal year (March 31, 2011), as previously planned.
Nearly one-third of people living with tuberculosis in the U.S. are unaware of their HIV status, according to a study published Friday in CDC's Morbidity and Mortality Weekly Report, Reuters reports (Dunham, Reuters, 10/25).
Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three months ended March 31, 2010.
StockPreacher.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
As the UN Special Rapporteur on maternal mortality in India points out there is a 'yawning gulf between commendable maternal mortality policies and their urgent, focused, sustained, systematic and effective implementation', the May issue of Reproductive Health Matters explores the causes and impact of this gap, but also highlights hopeful signs of progress.
› Verified 4 days ago
| Entity Name | Holicki Eye Centers, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811980386 PECOS PAC ID: 3476533324 Enrollment ID: O20040722000211 |
News Archive
Based on the preliminary findings from the ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial, Eisai Inc. announced today that the company will not submit marketing authorization applications to regulatory authorities in the United States, the European Union and Japan by the end of the fiscal year (March 31, 2011), as previously planned.
Nearly one-third of people living with tuberculosis in the U.S. are unaware of their HIV status, according to a study published Friday in CDC's Morbidity and Mortality Weekly Report, Reuters reports (Dunham, Reuters, 10/25).
Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three months ended March 31, 2010.
StockPreacher.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
As the UN Special Rapporteur on maternal mortality in India points out there is a 'yawning gulf between commendable maternal mortality policies and their urgent, focused, sustained, systematic and effective implementation', the May issue of Reproductive Health Matters explores the causes and impact of this gap, but also highlights hopeful signs of progress.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph Peter Holicki, DO 142 E Chicago Rd, Coldwater, MI 49036-8423 Ph: (517) 279-7927 | Joseph Peter Holicki, DO 142 E Chicago Rd, Coldwater, MI 49036-8423 Ph: (517) 279-7927 |
News Archive
Based on the preliminary findings from the ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial, Eisai Inc. announced today that the company will not submit marketing authorization applications to regulatory authorities in the United States, the European Union and Japan by the end of the fiscal year (March 31, 2011), as previously planned.
Nearly one-third of people living with tuberculosis in the U.S. are unaware of their HIV status, according to a study published Friday in CDC's Morbidity and Mortality Weekly Report, Reuters reports (Dunham, Reuters, 10/25).
Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced financial results for the three months ended March 31, 2010.
StockPreacher.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
As the UN Special Rapporteur on maternal mortality in India points out there is a 'yawning gulf between commendable maternal mortality policies and their urgent, focused, sustained, systematic and effective implementation', the May issue of Reproductive Health Matters explores the causes and impact of this gap, but also highlights hopeful signs of progress.
› Verified 4 days ago